258532-76-2

Usage

Uses

Used in Pharmaceutical Industry:
8-HYDROXY-2H-BENZO[B][1,4]OXAZIN-3(4H)-ONE is used as a synthetic intermediate for the production of various pharmaceuticals. Its unique structure allows it to be a key component in the development of new drugs with potential applications in treating different diseases.
Used in Agrochemical Industry:
In the agrochemical industry, 8-HYDROXY-2H-BENZO[B][1,4]OXAZIN-3(4H)-ONE is utilized as a synthetic intermediate for the creation of agrochemicals. Its incorporation in these products can contribute to the development of effective solutions for agricultural challenges, such as pest control and crop protection.
Used in Medicinal Chemistry Research:
8-HYDROXY-2H-BENZO[B][1,4]OXAZIN-3(4H)-ONE is used as a building block in organic synthesis for the development of compounds with diverse biological activities. Its derivatives are studied for their potential as antitumor, antibacterial, and antiviral agents, making it an important component in advancing medicinal chemistry research.
Used in Drug Discovery and Development:
As a valuable tool in drug discovery and development, 8-HYDROXY-2H-BENZO[B][1,4]OXAZIN-3(4H)-ONE aids researchers and scientists in their quest to find new and effective treatments for various medical conditions. Its versatile structure and properties make it an essential component in the design and synthesis of innovative drugs.

Upstream product

• 107-83-5 2-Methylpentane 
• 20734-66-1 1,2-dihydroxy-3-aminobenzene 
• 258532-71-7 8-methoxy-4H-benzo[1,4]oxazin-3-one 
• 888731-91-7 2-chloro-N-(2-hydroxy-3-methoxyphenyl)-acetamide 
• 15969-08-1 6-methoxy-2-nitrophenol 
• 40925-71-1 2-amino-6-methoxyphenol 
• 90-05-1 2-methoxy-phenol 

Downstream Products

• 258532-30-8 methyl (4-(2-(1,1-diphenyl-2,2,2-trifluoroethylthio)ethyl)-3,4-dihydro-2H-1,4-benzoxazin-8-yloxy)acetate 
• 258532-31-9 methyl (4-(2-(1,1-bis(4-fluorophenyl)ethylthio)ethyl)-3,4-dihydro-2H-1,4-benzoxazin-8-yloxy)acetate 
• 258532-38-6 methyl (4-(2-(1,1-diphenylethylthio)ethyl)-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-8-yloxy)acetate 
• 258532-33-1 methyl (4-(2-(2,2-diphenylpropylthio)ethyl)-3,4-dihydro-2H-1,4-benzoxazin-8-yloxy)acetate 
• 258532-29-5 methyl (4-(2-(1,1-diphenylethylthio)ethyl)-3,4-dihydro-2H-1,4-benzoxazin-8-yloxy)acetate 
• 258532-36-4 methyl (4-(2-(1,1-diphenylethoxy)ethyl)-3,4-dihydro-2H-1,4-benzoxazin-8-yloxy)acetate 
• 258532-84-2 8-acetoxy-4-(4,4-diphenylpentyl)-3-oxo-3,4-dihydro-2H-1,4-benzoxazine 
• 258532-83-1 8-acetoxy-4-(2-(1,1-diphenylethoxy)ethyl)-3-oxo-3,4-dihydro-2H-1,4-benzoxazine 
• 258532-28-4 methyl (4-(2-(diphenylmethylthio)ethyl)-3,4-dihydro-2H-1,4-benzoxazin-8-yloxy)acetate 
• 881830-06-4 acetic acid 4-(4,4-diphenyl-pentyl)-3,4-dihydro-2H-benzo[1,4]oxazin-8-yl ester 
• 881830-05-3 acetic acid 4-[2-(1,1-diphenyl-ethoxy)-ethyl]-3,4-dihydro-2H-benzo[1,4]oxazin-8-yl ester 
• 258532-32-0 methyl (4-(2-(1-methyl-1-phenylethylthio)ethyl)-3,4-dihydro-2H-1,4-benzoxazin-8-yloxy)acetate 
• 258532-89-7 4-(4,4-diphenylpentyl)-8-hydroxy-3-oxo-3,4-dihydro-2H-1,4-benzoxazine 
• 881830-02-0 [4-(2-benzylsulfanyl-ethyl)-3,4-dihydro-2H-benzo[1,4]oxazin-8-yloxy]-acetic acid methyl ester 

Relevant academic research and scientific papers

Production Method of Nitrogen-Containing Fused Ring Compounds

[Problems] The present invention provides a superior production method and a superior purification method of compounds effective for the treatment or prophylaxis of pathology showing involvement of uric acid, such as hyperuricemia, gouty tophus, acute gouty arthritis, chronic gouty arthritis, gouty kidney, urolithiasis, renal function disorder, coronary artery disease, ischemic heart disease and the like. [Means] A compound represented by the following formula [2] or a pharmaceutically acceptable salt thereof can be produced by reacting a compound represented by the following formula [3] or a salt thereof with a compound represented by the following formula [4], a salt thereof or a reactive derivative thereof. Moreover, crystallization of a compound represented by the formula [2] can be performed with industrially superior workability, and high quality crystals of a compound represented by the formula [2] can be obtained. wherein each symbol is as defined in the description.

Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds

[Problems] The present invention provides pharmaceutical composition which is effective for the prophylaxis or treatment of pathology showing involvement of uric acid (hyperuricemia, gouty tophus, acute gout arthritis, chronic gout arthritis, gouty kidney, urolithiasis, renal function disorder, coronary arterial disease, ischemic heart disease and the like) and the like, and is superior in the time-course stability and dissolution property (disintegration property). [Solving Means] The pharmaceutical composition of the present invention is a pharmaceutical composition comprising a nitrogen-containing fused ring compound represented by the following formula [1] or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable additives, wherein the nitrogen-containing fused ring compound or a pharmaceutically acceptable salt thereof is not in contact with a basic additive: wherein each symbol is as described in the specification.

Nitrogen-containing fused ring compounds and use thereof

A URAT1 activity inhibitor containing a nitrogen-containing fused ring compound represented by the following formula [1]: wherein each symbol is as defined in the description. The present invention is useful for the prophylaxis or treatment of pathology showing involvement of uric acid, such as hyperuricemia, gouty tophus, acute gouty arthritis, chronic gouty arthritis, gouty kidney, urolithiasis, renal function disorder, coronary artery disease, ischemic heart disease and the like.

Development of 3,4-dihydro-2H-benzo[1,4]oxazine derivatives as dual thromboxane A2 receptor antagonists and prostacyclin receptor agonists

We discovered a novel series of 3,4-dihydro-2H-benzo[1,4]oxazin-8- yloxyacetic acid derivatives as potent dual-acting agents to block the TXA 2 receptor and to activate the PGI2 receptor. We report the synthesis, structure-activity r

Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases

Compounds of the general formula (I): wherein the variables are as defined in the specification are useful for the prophylaxis or treatment of serotonin-related, especially 5-HT2receptor-related, diseases in human beings or animals, particularly diseases related to the 5-HT2creceptor, especially diseases such as eating disorders, memory disorders, schizophrenia, mood disorders, anxiety disorders, pain, sexual dysfunctionions, and urinary disorders.

Benzene fused heterocyclic derivatives having thromboxane A2 receptor antagonistic activity and prostaglandin I2 Agonistic activity and application thereof

Benzene fused derivatives represented by the following formula: having strong TXA2receptor antagonistic action and PGI2receptor agonistic action, and effective for treating or preventing diseases concerning TXA2.